Belvedere Trading
MCRB icon

Belvedere Trading’s Seres Therapeutics MCRB Stock Holding History

Belvedere Trading’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-24
Closed -$1.12K – 920
2023
Q3 		$1.12K Buy
+24
New +$1.83K ﹤0.01% 598
2021
Q3 		– Sell
-1,177
Closed -$488K – 538
2021
Q2 		$488K Buy
+1,177
New +$497K 0.04% 108
2021
Q1 		– Sell
-974
Closed -$477K – 320
2020
Q4 		$477K Buy
974
+308
+46% +$180K 0.02% 85
2020
Q3 		$377K Buy
+666
New +$221K 0.03% 30

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Belvedere Trading's MCRB Position: Q4 2023 in Review

Belvedere Trading sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 24 shares — an estimated $1.12K sold.

Belvedere Trading first reported a position in MCRB in Q3 2020 and held it in 4 quarters. The position peaked at $488K in Q2 2021. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

  • Belvedere Trading reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Belvedere Trading sold 24 Seres Therapeutics shares in Q4 2023, an estimated $1.12K.
  • Belvedere Trading first reported a position in Seres Therapeutics in Q3 2020 and held it in 4 quarters.
  • Belvedere Trading's Seres Therapeutics position peaked at $488K in Q2 2021.
  • 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on Belvedere Trading's 13F filing for Q4 2023, filed 13 Feb 2024.